TY  - JOUR
AU  - Milovanović, Jelena
AU  - Vujasinović, Tijana
AU  - Todorović-Raković, Nataša
AU  - Greenman, John
AU  - Hranisavljević, Jelena
AU  - Radulovic, Marko
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11982
AB  - Background: Vascular endothelial growth factor (VEGF) -A and -C act as multifunctional molecules and growth factors, while VE-cadherin (cadherin 5, CDH5) is the endothelial junction protein. Aim: To assess the relationship between intratumoral VEGF -A, -C and CDH5 levels and clinical outcome, in primary, early-stage, breast cancer patients. Patients and methods: The study included 69 node-negative (N0) breast cancer patients, all of whom had not received any prior hormonal or chemotherapeutic systemic therapy that would affect the course of disease. The median follow-up period was 144 months. Intratumoral mRNA levels of VEGF -A, -C and CDH5 were determined by RT-qPCR. Prognostic performance was evaluated by Cox proportional hazards regression, Kaplan-Meier analysis, as well as by the multivariable approach based on the least absolute shrinkage and selection operator (LASSO) logit regression. Classification of patients into the low and high subgroups was performed using the outcome-oriented cut-off point categorization approach. Results: Of the measured mRNAs, only CDH5 mRNA (t = −2.17; p = 0.04) and VEGF-C mRNA (t = −2.41; p = 0.03) showed significant differences between values in patient subgroups with distant metastasis and those without recurrences, respectively. These t-test results were in agreement with the Cox regression by which CDH5 mRNA reached the most pronounced hazard ratio (HR=2.07; p = 0.05), followed by VEGF-C mRNA (HR=1.59; p = 0.005). HR values above 1.0 indicate that high levels of either CDH5 or VEGF-C mRNAs associated with a higher risk of poor clinical outcome. Distant recurrence incidence was 26% for the CDH5high and 3% for the CDH5low subgroup (Kaplan–Meier analysis). Distant recurrence incidence was 23% for the VEGF-Chigh and 0% for VEGF-Clow subgroup. The independent prognostic value of VEGF-C mRNA was confirmed by LASSO regression. Conclusion: Intratumoral VEGF-A levels did not associate with disease outcome in primary, early-stage, breast cancer patients, whilst raised levels of either CDH5 or VEGF-C prognosticated a high risk of distant metastasis.
T2  - Pathology - Research and Practice
T1  - Vascular endothelial growth factor (VEGF) -A, -C and VE-cadherin as potential biomarkers in early breast cancer patients
VL  - 252
SP  - 154923
DO  - 10.1016/j.prp.2023.154923
ER  - 

@article{
author = "Milovanović, Jelena and Vujasinović, Tijana and Todorović-Raković, Nataša and Greenman, John and Hranisavljević, Jelena and Radulovic, Marko",
year = "2023",
abstract = "Background: Vascular endothelial growth factor (VEGF) -A and -C act as multifunctional molecules and growth factors, while VE-cadherin (cadherin 5, CDH5) is the endothelial junction protein. Aim: To assess the relationship between intratumoral VEGF -A, -C and CDH5 levels and clinical outcome, in primary, early-stage, breast cancer patients. Patients and methods: The study included 69 node-negative (N0) breast cancer patients, all of whom had not received any prior hormonal or chemotherapeutic systemic therapy that would affect the course of disease. The median follow-up period was 144 months. Intratumoral mRNA levels of VEGF -A, -C and CDH5 were determined by RT-qPCR. Prognostic performance was evaluated by Cox proportional hazards regression, Kaplan-Meier analysis, as well as by the multivariable approach based on the least absolute shrinkage and selection operator (LASSO) logit regression. Classification of patients into the low and high subgroups was performed using the outcome-oriented cut-off point categorization approach. Results: Of the measured mRNAs, only CDH5 mRNA (t = −2.17; p = 0.04) and VEGF-C mRNA (t = −2.41; p = 0.03) showed significant differences between values in patient subgroups with distant metastasis and those without recurrences, respectively. These t-test results were in agreement with the Cox regression by which CDH5 mRNA reached the most pronounced hazard ratio (HR=2.07; p = 0.05), followed by VEGF-C mRNA (HR=1.59; p = 0.005). HR values above 1.0 indicate that high levels of either CDH5 or VEGF-C mRNAs associated with a higher risk of poor clinical outcome. Distant recurrence incidence was 26% for the CDH5high and 3% for the CDH5low subgroup (Kaplan–Meier analysis). Distant recurrence incidence was 23% for the VEGF-Chigh and 0% for VEGF-Clow subgroup. The independent prognostic value of VEGF-C mRNA was confirmed by LASSO regression. Conclusion: Intratumoral VEGF-A levels did not associate with disease outcome in primary, early-stage, breast cancer patients, whilst raised levels of either CDH5 or VEGF-C prognosticated a high risk of distant metastasis.",
journal = "Pathology - Research and Practice",
title = "Vascular endothelial growth factor (VEGF) -A, -C and VE-cadherin as potential biomarkers in early breast cancer patients",
volume = "252",
pages = "154923",
doi = "10.1016/j.prp.2023.154923"
}

Milovanović, J., Vujasinović, T., Todorović-Raković, N., Greenman, J., Hranisavljević, J.,& Radulovic, M.. (2023). Vascular endothelial growth factor (VEGF) -A, -C and VE-cadherin as potential biomarkers in early breast cancer patients. in Pathology - Research and Practice, 252, 154923.
https://doi.org/10.1016/j.prp.2023.154923

Milovanović J, Vujasinović T, Todorović-Raković N, Greenman J, Hranisavljević J, Radulovic M. Vascular endothelial growth factor (VEGF) -A, -C and VE-cadherin as potential biomarkers in early breast cancer patients. in Pathology - Research and Practice. 2023;252:154923.
doi:10.1016/j.prp.2023.154923 .

Milovanović, Jelena, Vujasinović, Tijana, Todorović-Raković, Nataša, Greenman, John, Hranisavljević, Jelena, Radulovic, Marko, "Vascular endothelial growth factor (VEGF) -A, -C and VE-cadherin as potential biomarkers in early breast cancer patients" in Pathology - Research and Practice, 252 (2023):154923,
https://doi.org/10.1016/j.prp.2023.154923 . .